Warfarin mechanism of action –
**Core Concept**
Warfarin is an anticoagulant medication that acts by inhibiting the synthesis of vitamin K-dependent clotting factors in the liver, thereby prolonging the coagulation time.
**Why the Correct Answer is Right**
Warfarin competes with vitamin K for binding to the vitamin K epoxide reductase complex (VKORC1), an enzyme necessary for the gamma-carboxylation of vitamin K-dependent clotting factors (II, VII, IX, and X). By inhibiting VKORC1, warfarin reduces the production of these clotting factors, leading to a decrease in the formation of blood clots. This anticoagulant effect is dose-dependent and can be reversed by administering vitamin K.
**Why Each Wrong Option is Incorrect**
**Option A:** This is incorrect because Warfarin does not directly inhibit the activity of thrombin or other clotting enzymes; it affects the production of clotting factors.
**Option B:** This is incorrect because Warfarin does not work by inhibiting the activation of protein C or protein S; it affects the production of clotting factors that are activated by these proteins.
**Option C:** This is incorrect because Warfarin does not have a direct effect on platelet aggregation; it affects the coagulation cascade by reducing the production of clotting factors.
**Clinical Pearl / High-Yield Fact**
Warfarin has a narrow therapeutic index and requires regular monitoring of international normalized ratio (INR) to prevent bleeding complications. A significant decrease in INR may indicate a decrease in warfarin dose or an increase in vitamin K intake.
**Correct Answer: D. Inhibits the synthesis of vitamin K-dependent clotting factors by competing with vitamin K for binding to VKORC1.**